[CAS NO. 745013-59-6] Tremelimumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [745013-59-6]

Catalog

HY-P9918

Brand

MCE

CAS

745013-59-6

DESCRIPTION [745013-59-6]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Tremelimumab]

For research use only. We do not sell to patients.

Summary

Tremelimumab (Ticilimumab) is a fully humanized monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 ( CTLA-4 ) and can be used for metastatic melanoma research ^[1] .

In Vitro

Tremelimumab (Ticilimumab) has a higher affinity for CTLA-4-Ig than for CD28-Ig and that the antibody is specific for cynomolgus monkeys and humans ^[1] .
Tremelimumab does not bind to human leukocyte FcγR and does not trigger the release of cytokines avoiding the cytokine release syndrome, but increases the IL-2 production upon stimulation with the staphylococcal enterotoxin A in a concentration-dependent manner ^[1] .
Tremelimumab enhances the IL-2 production in T-cells ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01853618	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Heptocellular Cancer\|Biliary Tract Neoplasms\|Liver Cancer\|Hepatocellular Carcinoma\|Biliary Cancer	May 2, 2013	Phase 1\|Phase 2
NCT03101475	European Organisation for Research and Treatment of Cancer - EORTC	Colorectal Cancer\|Liver Metastases	November 23, 2018	Phase 2
NCT02261220	MedImmune LLC	Advanced Solid Tumors	October 13, 2014	Phase 1
NCT03144778	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7\|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7\|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7	July 12, 2017	Phase 1
NCT03283605	Centre hospitalier de l´Université de Montréal (CHUM)\|AstraZeneca	Head and Neck Squamous Cell Carcinoma\|Metastatic Squamous Cell Carcinoma	July 17, 2018	Phase 1\|Phase 2
NCT02551159	AstraZeneca	Squamous Cell Carcinoma of the Head and Neck	October 15, 2015	Phase 3
NCT03212469	Gustave Roussy, Cancer Campus, Grand Paris	Head and Neck Squamous Cell Carcinoma\|Lung Cancer\|Oesophageal Cancer	June 20, 2017	Phase 1\|Phase 2
NCT03202758	Centre Georges Francois Leclerc\|AstraZeneca	Colorectal Cancer Metastatic	August 29, 2017	Phase 1\|Phase 2
NCT02705482	MedImmune LLC	Select Advanced Solid Tumors	March 30, 2016	Phase 1
NCT03298451	AstraZeneca	Hepatocellular Carcinoma	October 11, 2017	Phase 3
NCT03598816	Washington University School of Medicine\|MedImmune LLC	Renal Cell Carcinoma	August 31, 2020	Phase 2
NCT03682068	AstraZeneca	Unresectable Locally Advanced Urothelial Cancer\|Metastatic Urothelial Cancer	September 27, 2018	Phase 3
NCT02718911	Eli Lilly and Company\|AstraZeneca	Solid Tumor	June 16, 2016	Phase 1
NCT03452332	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Advanced Cervical Adenocarcinoma\|Advanced Vaginal Carcinoma\|Advanced Vulvar Carcinoma\|Human Papillomavirus-Related Cervical Squamous Cell Carcinoma\|Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma\|Metastatic Cervical Adenocarcinoma\|Metastatic Cervical Carcinoma\|Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified\|Metastatic Vaginal Adenocarcinoma\|Metastatic Vaginal Carcinoma\|Metastatic Vulvar Carcinoma\|Recurrent Cervical Adenocarcinoma\|Recurrent Cervical Carcinoma\|Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified\|Recurrent Vaginal Carcinoma\|Recurrent Vulvar Carcinoma\|Stage III Cervical Cancer AJCC v8\|Stage III Vaginal Cancer AJCC v8\|Stage III Vulvar Cancer AJCC v8\|Stage IIIA Cervical Cancer AJCC v8\|Stage IIIA Vulvar Cancer AJCC v8\|Stage IIIB Cervical Cancer AJCC v8\|Stage IIIB Vulvar Cancer AJCC v8\|Stage IIIC Vulvar Cancer AJCC v8\|Stage IV Cervical Cancer AJCC v8\|Stage IV Vaginal Cancer AJCC v8\|Stage IV Vulvar Cancer AJCC v8\|Stage IVA Cervical Cancer AJCC v8\|Stage IVA Vaginal Cancer AJCC v8\|Stage IVA Vulvar Cancer AJCC v8\|Stage IVB Cervical Cancer AJCC v8\|Stage IVB Vaginal Cancer AJCC v8\|Stage IVB Vulvar Cancer AJCC v8\|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified\|Vulvar Adenocarcinoma\|Vulvar Squamous Cell Carcinoma	July 18, 2018	Phase 1
NCT02754856	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Metastatic Carcinoma in the Liver\|Resectable Mass\|Stage IV Colorectal Cancer AJCC v7\|Stage IVA Colorectal Cancer AJCC v7\|Stage IVB Colorectal Cancer AJCC v7	July 28, 2016	Phase 1
NCT03317158	Noah Hahn, M.D.\|AstraZeneca\|Hoosier Cancer Research Network	Urothelial Carcinoma\|Bladder Cancer	November 21, 2017	Phase 1\|Phase 2
NCT04238637	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest\|AstraZeneca	Intrahepatic Cholangiocarcinoma	November 1, 2019	Phase 2
NCT03539822	Anwaar Saeed\|AstraZeneca\|Exelixis\|University of Kansas Medical Center	Gastric Cancer\|Esophageal Adenocarcinoma\|Hepatocellular Carcinoma\|Colorectal Cancer	October 22, 2018	Phase 1\|Phase 2
NCT04395079	Jonsson Comprehensive Cancer Center\|AstraZeneca	Metastatic Malignant Female Reproductive System Neoplasm\|Platinum-Resistant Malignant Female Reproductive System Neoplasm\|Recurrent Malignant Female Reproductive System Neoplasm\|Refractory Malignant Female Reproductive System Neoplasm	August 7, 2020	Phase 2
NCT03275597	University of Wisconsin, Madison\|AstraZeneca	Non-small Cell Lung Cancer\|Non-small Cell Lung Cancer Stage IV	February 20, 2018	Phase 1
NCT03095274	Grupo Espanol de Tumores Neuroendocrinos	Neuroendocrine Tumors\|Neuroendocrine Neoplasm of Lung	April 11, 2017	Phase 2
NCT02485990	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca\|MedImmune LLC	Primary Peritoneal Carcinoma	January 8, 2016	Phase 1
NCT02821754	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Biliary Tract Neoplasms\|Liver Cancer\|Hepatocellular Carcinoma\|Cholangiocarcinoma\|Bile Duct Cancer	July 5, 2016	Phase 2
NCT02205333	MedImmune LLC	Advanced Solid Tumors\|Aggressive B-cell Lymphomas	August 13, 2014	Phase 1\|Phase 2
NCT03234153	University Hospital Inselspital, Berne\|AstraZeneca	Muscle-invasive Bladder Cancer	July 15, 2018	Phase 2
NCT03085849	Catherine Shu\|Columbia University	Extensive-stage Small Cell Lung Cancer	December 15, 2017	Phase 1
NCT03015129	Memorial Sloan Kettering Cancer Center	Endometrial Cancer\|Endometrial Carcinosarcoma\|Endometrial Carcinoma\|Endometrial Cancer Recurrent\|Endometrial Carcinoma, Recurrent	January 2017	Phase 2
NCT03923270	H. Lee Moffitt Cancer Center and Research Institute\|AstraZeneca	Small Cell Lung Cancer Extensive Stage\|Small-cell Lung Cancer	June 6, 2019	Phase 1
NCT02879162	Canadian Cancer Trials Group\|AstraZeneca	Advanced Rare Tumours	October 19, 2016	Phase 2
NCT02117219	MedImmune LLC	Myelodysplastic Syndrome	May 20, 2014	Phase 1
NCT02735239	Ludwig Institute for Cancer Research\|AstraZeneca	Esophageal Cancer	June 24, 2016	Phase 1\|Phase 2
NCT04817826	Gruppo Oncologico del Nord-Ovest	Gastric Cancer\|Microsatellite Instability	April 1, 2021	Phase 2
NCT02499328	AstraZeneca\|MedImmune LLC	Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck	August 6, 2015	Phase 1\|Phase 2
NCT05000710	Sheba Medical Center\|AstraZeneca\|Rambam Health Care Campus\|Tel-Aviv Sourasky Medical Center	Metastatic or Locally Advanced NSCLC	December 9, 2021	Phase 2
NCT03473574	AIO-Studien-gGmbH\|AstraZeneca	Cholangiocarcinoma\|Gall Bladder Carcinoma\|Cholangiocarcinoma Non-resectable\|Gallbladder Carcinoma Non-Resectable	May 2, 2018	Phase 2
NCT02340975	MedImmune LLC	Gastric or Gastroesophageal Junction Adenocarcinoma	March 31, 2015	Phase 1\|Phase 2
NCT04605731	City of Hope Medical Center\|National Cancer Institute (NCI)	BCLC Stage B Hepatocellular Carcinoma\|BCLC Stage C Hepatocellular Carcinoma\|Locally Advanced Hepatocellular Carcinoma\|Stage III Hepatocellular Carcinoma AJCC v8\|Stage IIIA Hepatocellular Carcinoma AJCC v8\|Stage IIIB Hepatocellular Carcinoma AJCC v8\|Stage IV Hepatocellular Carcinoma AJCC v8\|Stage IVA Hepatocellular Carcinoma AJCC v8\|Stage IVB Hepatocellular Carcinoma AJCC v8\|Unresectable Hepatocellular Carcinoma	August 3, 2021	Phase 1
NCT02626130	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Clear Cell Renal Cell Carcinoma\|Metastatic Renal Cell Cancer\|Stage IV Renal Cell Cancer AJCC v7	March 30, 2016	Early Phase 1
NCT02352948	AstraZeneca	Non - Small Cell Lung Cancer NSCLC	January 13, 2015	Phase 3
NCT03518606	UNICANCER\|National Cancer Institute, France\|AstraZeneca\|Pierre Fabre Laboratories	Advanced Solid Tumours\|Breast Cancer\|Head and Neck Cancer\|Cervix Cancer\|Prostate Cancer	June 20, 2018	Phase 1\|Phase 2
NCT02000947	MedImmune LLC	NSCLC\|Non-small Cell Lung Cancer\|Lung Cancer	October 25, 2013	Phase 1
NCT03022500	Seoul National University Hospital	Durvalumab &addition; Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC	May 18, 2017	Phase 2
NCT03802747	University of Colorado, Denver\|AstraZeneca	Colorectal Cancer	August 2019	Phase 1
NCT00702923	University of Wisconsin, Madison\|Pfizer	Prostate Cancer	July 2008	Phase 1
NCT03959293	Federation Francophone de Cancerologie Digestive\|AstraZeneca	Gastric Adenocarcinoma\|Gastric Cancer	July 17, 2019	Phase 2
NCT03549715	Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie	Infiltrating Bladder Urothelial Carcinoma	December 6, 2018	Phase 1\|Phase 2
NCT03007407	NSABP Foundation Inc	Colorectal Cancer Metastatic	July 31, 2017	Phase 2
NCT03075527	Dana-Farber Cancer Institute\|AstraZeneca	Mesothelioma	April 10, 2017	Phase 2
NCT02639026	Abramson Cancer Center of the University of Pennsylvania	Metastatic\|Melanoma\|Non Small Cell Lung Cancer (NSCLC)\|Breast Cancer\|Pancreatic Cancer	January 26, 2016	Phase 1
NCT03043872	AstraZeneca	Small Cell Lung Carcinoma Extensive Disease	March 27, 2017	Phase 3
NCT03509012	AstraZeneca	Carcinoma, Squamous Cell of Head and Neck\|Carcinoma, Non-Small-Cell Lung\|Small Cell Lung Carcinoma	May 2, 2018	Phase 1
NCT02369874	AstraZeneca	Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN	September 9, 2015	Phase 3
NCT01975831	Ludwig Institute for Cancer Research\|MedImmune LLC\|Cancer Research Institute, New York City	Breast Cancer\|Ovarian Cancer\|Colorectal Cancer\|Cervical Cancer\|Renal Cell Carcinoma	December 19, 2013	Phase 1
NCT00897312	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)	Melanoma	October 2006
NCT02586987	AstraZeneca	Lung Cancer\|Melanoma\|Head and Neck Carcinoma\|Gastroesophageal Cancer\|Breast Cancer\|Pancreatic Adenocarcinoma\|Colorectal Cancer\|Biliary Tract Cancer	December 28, 2015	Phase 1
NCT03057106	Canadian Cancer Trials Group\|AstraZeneca\|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano\|National Health and Medical Research Council, Australia	Lung Cancer Metastatic	February 15, 2017	Phase 2
NCT03430895	Memorial Sloan Kettering Cancer Center\|AstraZeneca	Non-Transitional Cell Carcinoma of the Urothelial Tract\|Small Cell of the Bladder\|Adenocarcinoma of the Bladder\|Squamous Cell Carcinoma of the Bladder\|Metastatic Bladder Cancer	January 31, 2018	Phase 2
NCT03482102	Massachusetts General Hospital\|AstraZeneca	Hepatocellular Carcinoma\|Biliary Tract Cancer	May 14, 2018	Phase 2
NCT03911557	John L. Villano, MD, PhD\|University of Kentucky	Tumor, Solid	June 8, 2019	Phase 2
NCT02962063	Memorial Sloan Kettering Cancer Center\|AstraZeneca	Esophageal Adenocarcinoma\|Gastroesophageal Junction Adenocarcinoma	November 2016	Phase 1\|Phase 2
NCT01103635	Abramson Cancer Center of the University of Pennsylvania	Recurrent Melanoma\|Stage IV Melanoma	February 2010	Phase 1
NCT03450967	Samsung Medical Center	Head and Neck Squamous Cell Carcinoma	April 11, 2018	Phase 2
NCT02888743	National Cancer Institute (NCI)	Metastatic Colorectal Carcinoma\|Metastatic Lung Non-Small Cell Carcinoma\|Stage IV Colorectal Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7\|Stage IVA Colorectal Cancer AJCC v7\|Stage IVB Colorectal Cancer AJCC v7	June 6, 2017	Phase 2
NCT03319316	European Organisation for Research and Treatment of Cancer - EORTC	Squamous Non-small Cell Lung Cancer\|Non-Squamous Non-small Cell Lung Cancer	November 1, 2018	Phase 2
NCT03703297	AstraZeneca	Small Cell Lung Cancer	September 27, 2018	Phase 3
NCT03410615	Canadian Cancer Trials Group\|AstraZeneca	Oropharyngeal Squamous Cell Carcinoma	January 31, 2018	Phase 2
NCT03005002	City of Hope Medical Center\|National Cancer Institute (NCI)	Metastatic Carcinoma in the Liver\|MLH1 Gene Mutation\|MSH6 Gene Mutation\|PMS2 Gene Mutation\|Stage IV Colorectal Cancer\|Stage IVA Colorectal Cancer\|Stage IVB Colorectal Cancer	June 28, 2017	Phase 1
NCT02701400	Emory University\|AstraZeneca	Recurrent Small Cell Lung Carcinoma	April 14, 2016	Phase 2
NCT05027425	Davendra Sohal\|University of Cincinnati	Hepatocellular Carcinoma\|Cirrhosis\|Portal Hypertension	December 7, 2021	Phase 2
NCT05345678	AstraZeneca	Unresectable Hepatocellular Carcinoma
NCT03206073	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Colorectal Cancer\|Colorectal Carcinoma\|Colorectal Adenocarcinoma\|Refractory Cancer\|Colorectal Neoplasms	December 7, 2017	Phase 1\|Phase 2
NCT02716805	Ludwig Institute for Cancer Research\|MedImmune LLC\|Cancer Research Institute, New York City\|Multiple Myeloma Research Foundation	Multiple Myeloma	December 13, 2016	Phase 1
NCT02549651	MedImmune LLC	Diffuse Large B-Cell Lymphoma	July 13, 2016	Phase 1
NCT02301130	Kyowa Kirin, Inc.\|AstraZeneca	Advanced Solid Tumors	November 26, 2014	Phase 1
NCT04034927	National Cancer Institute (NCI)\|NRG Oncology	Fallopian Tube Endometrioid Tumor\|Fallopian Tube High Grade Serous Adenocarcinoma\|Malignant Ovarian Endometrioid Tumor\|Ovarian High Grade Serous Adenocarcinoma\|Platinum-Sensitive Fallopian Tube Carcinoma\|Platinum-Sensitive Ovarian Carcinoma\|Platinum-Sensitive Primary Peritoneal Carcinoma\|Primary Peritoneal High Grade Serous Adenocarcinoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Fallopian Tube Endometrioid Adenocarcinoma\|Recurrent Ovarian Endometrioid Adenocarcinoma\|Recurrent Ovarian Serous Adenocarcinoma\|Recurrent Primary Peritoneal Carcinoma\|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma	October 11, 2019	Phase 2
NCT03702179	Spanish Oncology Genito-Urinary Group\|AstraZeneca\|MFAR	Invasive Bladder Cancer	November 19, 2018	Phase 2
NCT02040064	Gustave Roussy, Cancer Campus, Grand Paris\|AstraZeneca	Non Small Cell Lung Cancer	January 2014	Phase 1
NCT05383001	AIO-Studien-gGmbH\|AstraZeneca	NSCLC Stage IV	May 20, 2022	Phase 2
NCT03164772	Ludwig Institute for Cancer Research\|Cancer Research Institute (CRI)\|Boehringer Ingelheim\|MedImmune LLC\|CureVac\|PharmaJet, Inc.	Metastatic Non-small Cell Lung Cancer\|NSCLC	December 20, 2017	Phase 1\|Phase 2
NCT04430452	Mary Feng, MD\|AstraZeneca\|University of California, San Francisco	Advanced Hepatocellular Carcinoma\|Stage III Hepatocellular Carcinoma AJCC v8\|Stage IIIA Hepatocellular Carcinoma AJCC v8\|Stage IIIB Hepatocellular Carcinoma AJCC v8\|Stage IV Hepatocellular Carcinoma AJCC v8\|Stage IVA Hepatocellular Carcinoma AJCC v8\|Stage IVB Hepatocellular Carcinoma AJCC v8	February 4, 2022	Phase 2
NCT02953457	Roswell Park Cancer Institute\|AstraZeneca	BRCA1 Gene Mutation\|BRCA2 Gene Mutation\|Ovarian Serous Adenocarcinoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Primary Peritoneal Carcinoma	June 29, 2017	Phase 2
NCT03204812	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Castration-Resistant Prostate Carcinoma\|Metastatic Malignant Neoplasm in the Bone\|Prostate Adenocarcinoma\|Stage IV Prostate Cancer AJCC v8\|Stage IVA Prostate Cancer AJCC v8\|Stage IVB Prostate Cancer AJCC v8	July 14, 2017	Phase 2
NCT02141347	AstraZeneca	Part A and B: Advanced Solid Malignancies\|Part C: Malignant Mesothelioma	May 22, 2014	Phase 1
NCT02812420	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Hydronephrosis\|Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant\|Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant\|Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant\|Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant\|Renal Pelvis Urothelial Carcinoma\|Stage II Bladder Urothelial Carcinoma AJCC v6 and v7\|Stage II Renal Pelvis Cancer AJCC v7\|Stage II Ureter Cancer AJCC v7\|Stage II Urethral Cancer AJCC v7\|Stage III Bladder Urothelial Carcinoma AJCC v6 and v7\|Stage III Renal Pelvis Cancer AJCC v7\|Stage III Ureter Cancer AJCC v7\|Stage III Urethral Cancer AJCC v7\|Stage IV Renal Pelvis Cancer AJCC v7\|Stage IV Ureter Cancer AJCC v7\|Stage IV Urethral Cancer AJCC v7\|Ureter Urothelial Carcinoma\|Urethral Urothelial Carcinoma	March 7, 2017	Early Phase 1
NCT04159974	University of Cologne\|AstraZeneca	Esophageal Adenocarcinoma	September 30, 2019	Phase 2
NCT05301842	AstraZeneca	Hepatocellular Carcinoma	March 28, 2022	Phase 3
NCT04221555	Asan Medical Center	Resectable Gastric or Gastroesophageal Junction Adenocarcinoma	May 13, 2020	Phase 2
NCT02937818	AstraZeneca	Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma	November 28, 2016	Phase 2
NCT02938793	Prisma Health-Upstate\|AstraZeneca\|MedImmune LLC	Cancer\|Rare Disease	December 1, 2016	Phase 2
NCT03385655	Canadian Cancer Trials Group\|Canadian Cancer Clinical Trials Network\|BC Cancer Foundation	Prostate Cancer	December 12, 2017	Phase 2
NCT03871036	The Netherlands Cancer Institute\|AstraZeneca	Urothelial Carcinoma	May 1, 2019	Phase 1\|Phase 2
NCT02588131	Italian Network for Tumor Biotherapy Foundation\|AstraZeneca	Pleural Mesothelioma\|Peritoneal Mesothelioma	October 2015	Phase 2
NCT04169841	Centre Georges Francois Leclerc\|AstraZeneca	Immunotherapy	February 10, 2020	Phase 2
NCT02563925	Memorial Sloan Kettering Cancer Center\|MedImmune LLC	Metastatic Breast Cancer	September 18, 2015	Not Applicable
NCT03581487	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Lung Non-Small Cell Carcinoma\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	April 1, 2019	Phase 1\|Phase 2
NCT03132467	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Anatomic Stage II Breast Cancer AJCC v8\|Anatomic Stage IIA Breast Cancer AJCC v8\|Anatomic Stage IIB Breast Cancer AJCC v8\|Anatomic Stage III Breast Cancer AJCC v8\|Anatomic Stage IIIA Breast Cancer AJCC v8\|Anatomic Stage IIIB Breast Cancer AJCC v8\|Anatomic Stage IIIC Breast Cancer AJCC v8\|Estrogen Receptor Positive\|HER2+Neu Negative\|Progesterone Receptor Positive\|Prognostic Stage II Breast Cancer AJCC v8\|Prognostic Stage IIA Breast Cancer AJCC v8\|Prognostic Stage IIB Breast Cancer AJCC v8\|Prognostic Stage III Breast Cancer AJCC v8\|Prognostic Stage IIIA Breast Cancer AJCC v8\|Prognostic Stage IIIB Breast Cancer AJCC v8\|Prognostic Stage IIIC Breast Cancer AJCC v8	June 13, 2017	Early Phase 1
NCT03046862	Seoul National University Hospital	Biliary Tract Neoplasms	February 25, 2017	Phase 2
NCT05380713	University Health Network, Toronto\|OICR	Mesothelioma, Malignant	May 9, 2022	Phase 2
NCT02535078	Immunocore Ltd\|AstraZeneca	Malignant Melanoma	November 2015	Phase 1\|Phase 2
NCT03150836	Terence Friedlander, MD\|MedImmune LLC\|University of California, San Francisco	Bladder Cancer	October 1, 2017	Phase 2
NCT05063565	Boston Scientific Corporation\|Biocompatibles UK Ltd	Hepatocellular Carcinoma	December 2022	Phase 2
NCT03975114	National Cancer Institute, Naples\|University of Campania Luigi Vanvitelli\|AstraZeneca	Carcinoma, Non-Small-Cell Lung	December 20, 2018	Phase 2
NCT05120622	University of British Columbia	Bladder Cancer\|High-Risk Cancer\|Tremelimumab\|Durvalumab\|Non-muscle Invasive	September 1, 2021	Phase 1\|Phase 2
NCT03638141	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca	Intermediate Stage of Hepatocellular Carcinoma\|Hepatocellular Carcinoma	October 2, 2019	Phase 2
NCT04287894	The Netherlands Cancer Institute\|AstraZeneca	Stage III NSCLC	December 28, 2018	Phase 1
NCT03737968	Yonsei University	Stage II-IVB Operable HNSCC Oral Cavity\|Hypopharynx\|Oropharynx\|Larynx	January 2, 2019	Phase 2
NCT01843374	MedImmune LLC	Unresectable Pleural or Peritoneal Malignant Mesothelioma	May 17, 2013	Phase 2
NCT02592551	Baylor College of Medicine	Mesothelioma	May 11, 2016	Phase 2
NCT05440864	University Health Network, Toronto\|Clinica Universidad de Navarra, Universidad de Navarra\|University of Milan	Hepatocellular Carcinoma	January 2023	Phase 2
NCT03373760	Southwest Oncology Group\|National Cancer Institute (NCI)	Recurrent Squamous Cell Lung Carcinoma\|Stage IV Squamous Cell Lung Carcinoma AJCC v7	October 2, 2017	Phase 2
NCT03158064	Memorial Sloan Kettering Cancer Center\|AstraZeneca	Germ Cell Tumor\|Nonseminomatous Germ Cell Tumor\|Seminoma\|Germinomatous Germ Cell Tumor\|Dysgerminoma\|Pineal Germ Cell Tumor	May 15, 2017	Phase 2
NCT02819596	Queen Mary University of London\|Vall d´Hebron Institute of Oncology\|AstraZeneca	Renal Clear Cell Carcinoma\|Renal Papillary Cell Carcinoma	January 2017	Phase 2
NCT03122509	Memorial Sloan Kettering Cancer Center\|MedImmune LLC\|AstraZeneca	Metastatic Colorectal Cancer	April 24, 2017	Phase 2
NCT02262741	MedImmune LLC	Squamous Cell Carcinoma of the Head and Neck	October 15, 2014	Phase 1
NCT02643303	Ludwig Institute for Cancer Research\|MedImmune LLC\|Cancer Research Institute, New York City	Head and Neck Squamous Cell Carcinoma\|Breast Cancer\|Sarcoma\|Merkel Cell Carcinoma\|Cutaneous T-Cell Lymphoma\|Melanoma\|Renal Cancer\|Bladder Cancer\|Prostate Cancer\|Testicular Cancer\|Solid Tumor	December 28, 2016	Phase 1\|Phase 2
NCT03277482	Dana-Farber Cancer Institute\|AstraZeneca	Recurrent Gynecological Cancer\|Metastatic Cervical Cancer\|Metastatic Ovarian Cancer\|Metastatic Vaginal Cancer\|Metastatic Vulvar Cancer\|Metastatic Endometrial Cancer\|Recurrent Cervical Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Vaginal Cancer\|Recurrent Vulvar Cancer\|Recurrent Endometrial Cancer	June 1, 2018	Phase 1
NCT05239169	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Biliary Tract Cancer (CCA)\|Intrahepatic Cholangiocarcinoma\|Hilar Cholangiocarcinoma\|Distal Cholangiocarcinoma\|Gall Bladder Carcinoma	May 23, 2022	Phase 2
NCT02537418	Canadian Cancer Trials Group\|AstraZeneca	Solid Malignancies	October 1, 2015	Phase 1
NCT01655888	Azienda Ospedaliera Universitaria Senese\|MedImmune LLC	Malignant Mesothelioma	July 2012	Phase 2
NCT03084471	AstraZeneca	Advanced Solid Malignancies	June 5, 2017	Phase 3
NCT02815995	M.D. Anderson Cancer Center\|MedImmune LLC	Advanced and+or Metastatic Sarcoma	August 16, 2016	Phase 2
NCT03693612	GlaxoSmithKline\|MedImmune LLC	Neoplasms	November 26, 2018	Phase 1\|Phase 2
NCT05154994	University of Utah\|National Cancer Institute (NCI)	Infiltrating Urothelial Carcinoma, Sarcomatoid Variant\|Locally Advanced Urothelial Carcinoma\|Metastatic Urothelial Carcinoma\|Unresectable Urothelial Carcinoma	January 14, 2022	Phase 1
NCT02516241	AstraZeneca	Urothelial Cancer	November 2, 2015	Phase 3
NCT04073160	Daniel George, MD\|AstraZeneca\|Duke University	Bladder Cancer	June 2020	Phase 1
NCT02453282	AstraZeneca	Non-Small-Cell Lung Carcinoma NSCLC	July 21, 2015	Phase 3
NCT02311361	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Pancreatic Neoplasms\|Pancreatic Cancer\|Cancer of Pancreas\|Cancer of the Pancreas\|Pancreas Cancer	March 25, 2015	Phase 1\|Phase 2
NCT03522584	University of Washington\|National Cancer Institute (NCI)\|AstraZeneca	Metastatic Head and Neck Squamous Cell Carcinoma\|Recurrent Head and Neck Squamous Cell Carcinoma	May 17, 2018	Phase 1\|Phase 2
NCT03994393	University of Sydney\|AstraZeneca\|Australasian Lung Cancer Trials Group	EGFR Mutant Advanced Non Small Cell Lung Cancer	October 23, 2018	Phase 2
NCT02978482	AstraZeneca	Advanced Malignancy	December 1, 2016	Phase 1
NCT04960709	AstraZeneca	Muscle Invasive Bladder Cancer	October 20, 2017	Phase 3
NCT02141542	F. Stephen Hodi, MD\|MedImmune LLC\|Dana-Farber Cancer Institute	Metastatic Melanoma	May 2014	Phase 1
NCT03847649	Canadian Cancer Trials Group\|AstraZeneca	Cancer	June 7, 2019	Phase 2
NCT03081923	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano\|AstraZeneca	Germ Cell Tumor	February 1, 2017	Phase 2
NCT02527434	AstraZeneca	Urothelial Bladder Cancer\|Triple-negative Breast Cancer\|Pancreatic Ductal Adenocarcinoma	November 2, 2015	Phase 2
NCT03601455	Jonsson Comprehensive Cancer Center\|AstraZeneca	Bladder Urothelial Carcinoma\|Stage IV Bladder Cancer AJCC v8\|Stage IVA Bladder Cancer AJCC v8\|Stage IVB Bladder Cancer AJCC v8	October 26, 2018	Phase 2
NCT02179671	AstraZeneca\|Quintiles, Inc.	Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)	July 25, 2014	Phase 2
NCT02879318	Canadian Cancer Trials Group\|AstraZeneca	Pancreatic Adenocarcinoma	August 22, 2016	Phase 2
NCT02868632	NYU Langone Health\|AstraZeneca	Pancreatic Cancer	August 7, 2016	Phase 1
NCT03704480	GERCOR - Multidisciplinary Oncology Cooperative Group\|AstraZeneca	Advanced Biliary Tract Carcinoma	November 9, 2018	Phase 2
NCT03624231	Ulrich Keilholz\|Charite University, Berlin, Germany\|AstraZeneca	Squamous Cell Carcinoma of the Head and Neck	August 15, 2018	Phase 2
NCT04274816	A.J.M. van den Eertwegh\|Amsterdam UMC, location VUmc	Cutaneous Melanoma	July 10, 2012	Phase 1
NCT05451043	AHS Cancer Control Alberta	Pancreatic Cancer\|Hepatocellular Cancer\|Biliary Tract Cancer\|Cholangiocarcinoma	October 1, 2022	Phase 2
NCT03426657	University of Erlangen-Nürnberg Medical School	Locally Advanced Head and Neck Squamous Cell Carcinoma	September 20, 2018	Phase 2
NCT04156087	Baki Topal\|AstraZeneca\|University Hospital, Gasthuisberg	Pancreatic Cancer Non-resectable	May 9, 2020	Phase 2
NCT01938612	AstraZeneca	Advanced Solid Tumors	September 12, 2013	Phase 1
NCT03965468	ETOP IBCSG Partners Foundation\|AstraZeneca	Non-small Cell Lung Cancer\|Stage IV\|Oligometastasis	November 19, 2019	Phase 2
NCT03606967	National Cancer Institute (NCI)	Anatomic Stage IV Breast Cancer AJCC v8\|Invasive Breast Carcinoma\|Metastatic Triple-Negative Breast Carcinoma	December 14, 2018	Phase 2
NCT03122496	Memorial Sloan Kettering Cancer Center\|AstraZeneca	Metastatic Anaplastic Thyroid Cancer	April 25, 2017	Phase 1
NCT03164616	AstraZeneca	Non Small Cell Lung Cancer NSCLC	June 1, 2017	Phase 3
NCT03937830	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Hepatocellular Cancer\|Hepatocellular Carcinoma\|Metastatic Hepatocellular Carcinoma	March 10, 2021	Phase 2
NCT03753919	Grupo Espanol de Tumores Neuroendocrinos\|MFAR	Metastatic Thyroid Papillary Carcinoma\|Metastatic Thyroid Follicular Carcinoma\|Metastatic Thyroid Cancer	April 2, 2019	Phase 2
NCT02154490	Southwest Oncology Group\|National Cancer Institute (NCI)	Recurrent Squamous Cell Lung Carcinoma\|Stage IV Squamous Cell Lung Carcinoma AJCC v7	June 16, 2014
NCT04625699	Catherine Shu\|Columbia University	Nonsmall Cell Lung Cancer	December 2022	Phase 2
NCT02319044	AstraZeneca\|PRA Health Sciences	Recurrent+Metastatic Squamous Cell Carcinoma of Head & Neck	April 15, 2015	Phase 2
NCT03699449	Yonsei University\|AstraZeneca\|Samsung Genomic Institute\|Seoul National University Hospital\|Samsung Medical Center\|Korean Gynecologic Oncology Group	Platinum-resistant Recurrent Ovarian Cancer	November 26, 2018	Phase 2
NCT03982173	Gustave Roussy, Cancer Campus, Grand Paris	Metastatic Colorectal Cancer\|Triple Negative Breast Cancer\|Prostate Adenocarcinoma\|Stomach Adenocarcinoma\|Esophageal Adenocarcinoma	April 15, 2019	Phase 2
NCT05557838	AstraZeneca	Hepatocellular Carcinoma	November 30, 2022	Phase 3
NCT03026062	M.D. Anderson Cancer Center	Platinum-Resistant Fallopian Tube Carcinoma\|Platinum-Resistant Ovarian Carcinoma\|Platinum-Resistant Primary Peritoneal Carcinoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Primary Peritoneal Carcinoma\|Refractory Fallopian Tube Carcinoma\|Refractory Ovarian Carcinoma\|Refractory Primary Peritoneal Carcinoma	May 18, 2017	Phase 2
NCT02788773	Canadian Cancer Trials Group\|AstraZeneca	Prostate Cancer	August 18, 2016	Phase 2
NCT02870920	Canadian Cancer Trials Group\|AstraZeneca	Colorectal Cancer	August 10, 2016	Phase 2
NCT03784066	Universitaire Ziekenhuizen KU Leuven\|AstraZeneca\|European Organisation for Research and Treatment of Cancer - EORTC\|Vlaams Instituut voor Biotechnologie (VIB)	Oral Cavity Squamous Cell Carcinoma	August 27, 2018	Phase 1\|Phase 2
NCT04107168	CCTU- Cancer Theme\|Microbiotica Ltd\|Cambridge University Hospitals NHS Foundation Trust	Melanoma\|Renal Cancer\|Lung Cancer	July 8, 2020
NCT03472274	Fundacion CRIS de Investigación para Vencer el Cáncer\|AstraZeneca\|Apices Soluciones S.L.	Bladder Cancer	October 25, 2018	Phase 2
NCT03288532	University College, London\|AstraZeneca\|Kidney Cancer UK\|Cancer Research UK	Renal Cell Carcinoma	July 19, 2018	Phase 3
NCT03608865	Yonsei University	Metastatic Breast Cancer	September 19, 2017	Phase 2
NCT03237377	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca	Non-Small Cell Lung Cancer	December 12, 2017	Phase 2
NCT03963414	Vinicius Ernani\|AstraZeneca\|University of Nebraska	Small Cell Lung Carcinoma	June 5, 2020	Phase 1
NCT02571725	New Mexico Cancer Care Alliance	Ovarian Cancer\|Fallopian Tube Cancer\|Peritoneal Neoplasms	February 23, 2016	Phase 1\|Phase 2
NCT03317457	AIO-Studien-gGmbH\|AstraZeneca	Metastatic Adult Soft Tissue Sarcoma\|Recurrent Adult Soft Tissue Sarcoma	December 15, 2017	Phase 2
NCT01649024	Azienda Ospedaliera Universitaria Senese	Malignant Mesothelioma	May 2009	Phase 2
NCT03837899	AstraZeneca	Pediatric Cancer\|Solid Tumor Pediatric\|Hematological Malignancies	March 7, 2019	Phase 1\|Phase 2
NCT02762006	Moshe Ornstein\|Case Comprehensive Cancer Center	Renal Cell Carcinoma\|Kidney Cancer	December 20, 2016	Phase 1
NCT02616185	Pfizer	Prostatic Neoplasms	December 30, 2015	Phase 1
NCT04988945	The University of Hong Kong	HCC	December 1, 2020	Phase 2
NCT03089645	MedImmune LLC	Advanced Solid Tumors	March 21, 2017	Phase 1
NCT02794883	Northwestern University\|AstraZeneca\|MedImmune LLC\|National Cancer Institute (NCI)	Malignant Glioma\|Recurrent Glioblastoma	November 1, 2016	Phase 2
NCT03618134	Jonsson Comprehensive Cancer Center\|AstraZeneca	Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8\|Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8\|Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8\|Human Papillomavirus Positive\|Oropharyngeal Squamous Cell Carcinoma\|p16 Positive Neoplastic Cells Present\|Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8\|Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8\|Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	October 4, 2018	Phase 1\|Phase 2
NCT04522544	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest\|AstraZeneca	Hepatocellular Carcinoma Non-resectable	December 15, 2020	Phase 2
NCT02536794	Northwestern University\|MedImmune LLC\|Avon Breast Cancer Foundation\|National Cancer Institute (NCI)	Estrogen Receptor Negative\|Estrogen Receptor Positive\|HER2+Neu Negative\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer	January 14, 2016	Phase 2
NCT02658214	AstraZeneca	Small Cell Lung Carcinoma\|Carcinoma, Squamous Cell of Head and Neck\|Stomach Neoplasms\|Triple Negative Breast Neoplasms\|Ovarian Neoplasms\|Fallopian Tube Neoplasms\|Peritoneal Neoplasms\|Esophagogastric Junction Neoplasms\|Carcinoma, Pancreatic Ductal\|Esophageal Squamous Cell Carcinoma	April 28, 2016	Phase 1
NCT03130764	Columbia University	Non-small Cell Lung Cancer	March 2017	Phase 2
NCT00378482	AstraZeneca	Colorectal Neoplasms\|Melanoma\|Prostatic Neoplasms\|Renal Cell Carcinoma\|Neoplasms\|Patients Who Have+Have Had Melanoma and Other Tumors	March 5, 2007	Phase 2
NCT02519348	MedImmune LLC	Hepatocellular Carcinoma	October 19, 2015	Phase 2
NCT02029001	Centre Leon Berard\|National Cancer Institute, France	Malignant Solid Neoplasms	March 2014	Phase 2
NCT03557918	Matthew Galsky\|AstraZeneca\|Hoosier Cancer Research Network	Urothelial Carcinoma	November 12, 2018	Phase 2

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Comin-Anduix B, et al. Tremelimumab: research and clinical development. Onco Targets Ther. 2016 Mar 23;9:1767-76.